QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) | |
(Address of Principal Executive Offices) |
(Zip Code) |
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered | ||
☒ | Accelerated filer | ☐ | ||||
Non-accelerated filer | ☐ | Smaller reporting company | ||||
Emerging growth company |
Incorporated by Reference |
||||||||||||||||||||||
Exhibit Number |
Description of Exhibit |
Form |
File Number |
Date of Filing |
Exhibit Number |
Filed Herewith |
||||||||||||||||
31.1 | Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended | X | ||||||||||||||||||||
31.2 | Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended | X | ||||||||||||||||||||
101.INS | Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are not embedded within the Inline XBRL document | X | ||||||||||||||||||||
101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | ||||||||||||||||||||
101.CAL | Inline XBRL Taxonomy Calculation Linkbase Document | X | ||||||||||||||||||||
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | ||||||||||||||||||||
101.LAB | Inline XBRL Taxonomy Label Linkbase Document | X | ||||||||||||||||||||
101.PRE | Inline XBRL Taxonomy Presentation Linkbase Document | X | ||||||||||||||||||||
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101.INS) | X |
AGIOS PHARMACEUTICALS, INC. | ||||||
May 7, 2021 | By: | /s/ Jacqualyn A. Fouse | ||||
Jacqualyn A. Fouse, Ph.D. | ||||||
Chief Executive Officer (principal executive officer) | ||||||
May 7, 2021 | By: | /s/ Jonathan Biller | ||||
Jonathan Biller | ||||||
Chief Financial Officer and Head of Legal and Corporate Affairs (principal financial officer) |
Exhibit 31.1
CERTIFICATION
I, Jacqualyn A. Fouse, certify that:
1. | I have reviewed this Quarterly Report on Form 10-Q/A of Agios Pharmaceuticals, Inc.; and |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. |
May 7, 2021 | By: | /s/ Jacqualyn A. Fouse | ||||
Jacqualyn A. Fouse, Ph.D. | ||||||
Chief Executive Officer (principal executive officer) |
Exhibit 31.2
CERTIFICATION
I, Jonathan Biller, certify that:
1. | I have reviewed this Quarterly Report on Form 10-Q/A of Agios Pharmaceuticals, Inc.; and |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. |
May 7, 2021 | By: | /s/ Jonathan Biller | ||||
Jonathan Biller | ||||||
Chief Financial Officer and Head of Legal and Corporate Affairs (principal financial officer) |